ArticleFrontiers in oncology2025
The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predicting the prognosis of breast cancer patients by using nutrition-based index: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of sarcopenia in patients with nasopharyngeal carcinoma: a meta-analysis.Annals of medicine · 2025Pooled it
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
- Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.Frontiers in oncology · 2026Review
- The relationship between sarcopenia and breast cancer: mechanistic pathways and clinical relevance.Frontiers in cell and developmental biology · 2026Review
- The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer.Annals of medicine · 2025Article
- Intervention strategies for cancer-related sarcopenia: a scoping review.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study efforts to explore the association between sarcopenia, an age-related decline in muscle mass and physical function, and clinical outcomes in women with triple-negative breast cancer (TNBC). Methods and materials: This retrospective study included women diagnosed with TNBC who received breast surgery from December 2012 to December 2018. Skeletal muscle mass index (SMI) is utilized to evaluate sarcopenia, which was quantified by the cross-sectional area of muscle at the twelfth thoracic vertebra (T12). Disease-free survival (DFS) and overall survival (OS) are the endpoints. The association of sarcopenia with DFS and OS was statistically analyzed. Results: The study included 130 women in all, with a median age of 55 years (median follow-up, 53 months). Among them, 78 (58.5%) women had sarcopenia (SMI <28.01). 38 patients (29.2%) died and 49 patients (37.7%) experienced a recurrence of breast cancer throughout the follow-up period. Sarcopenia was demonstrated to be a significant predictive factor for both OS (HR,2.885; 95% CI, 1.349-6.169; p = 0.006) and DFS (HR,3.121; 95% CI, 1.578-6.175; p = 0.001) in the multivariate Cox proportional hazard model. There was no significant correlation seen between body mass index and either DFS (p = 0.156) or OS (P = 0.264). Logistic regression model further revealed that sarcopenia was a prognostic factor that was independently associated with both DFS (p = 0.001) and OS (p = 0.006). Conclusions: Among women with TNBC, sarcopenia is associated with worse clinical outcomes. These patients with high risk might be candidates for individual programmed exercise and diet interventions to optimize survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.